Geoffrey is the Chief Innovation Officer for Indigo. He is also a Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is a co-founder of Indigo, Seres Therapeutics, Axcella Health, Kaleido Biosciences, and others.
Geoffrey served as Chief Technology Officer at Seres Therapeutics, where he led the build-out of the Microbiome Therapeutics platform and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic, and VP Product Discovery at Axcella, where he led discovery of two clinically-validated drug candidates.
Geoffrey has been named as an inventor on over 100 patents and applications and received more than 20 awards for invention, including the Lemelson-MIT student prize, given to the most innovative student at MIT. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.